Thomas Goddemeier
Impact in
- Oncology top 5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Papers in
- Oncology 12
- Cancer-related Molecular Pathways 4
- Colorectal Cancer Treatments and Studies 3
-
- Lung Cancer Treatments and Mutations 10
- Lung Cancer Diagnosis and Treatment 2
- Co-authors
- Wilfried Eberhardt (4 shared papers)Robert Pirker (4 shared papers)Joachim von Pawel (4 shared papers)Kenneth J. O’Byrne (3 shared papers)Filippo de Marinis (3 shared papers)Ihor Vynnychenko (3 shared papers)U. Gatzemeier (3 shared papers)Maciej Krzakowski (3 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Investigational New Drugs (2 papers)Lung Cancer (2 papers)Annals of Oncology (2 papers)British Journal of Cancer (1 paper)
- Partner nations
- GermanyUnited KingdomUnited States
In The Last Decade
Thomas Goddemeier
18 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 966
- Pulmonary and Respiratory Medicine 930
- Cancer Research 179
- Otorhinolaryngology 29
- Hepatology 43
Countries citing papers authored by Thomas Goddemeier
This map shows the geographic impact of Thomas Goddemeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Goddemeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Goddemeier more than expected).
Fields of papers citing papers by Thomas Goddemeier
This network shows the impact of papers produced by Thomas Goddemeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Goddemeier. The network helps show where Thomas Goddemeier may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Goddemeier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Hit paper breakdown → | 2009 | 1046 |
| 2 | 2010 | 88 | |
| 3 | 2014 | 46 | |
| 4 | 2022 | 31 | |
| 5 | 2013 | 29 | |
| 6 | 2021 | 26 | |
| 7 | 2024 | 20 | |
| 8 | 2018 | 15 | |
| 9 | 2021 | 12 | |
| 10 | 2022 | 5 | |
| 11 | 2012 | 5 | |
| 12 | 2017 | 5 | |
| 13 | 2018 | 4 | |
| 14 | 2006 | 3 | |
| 15 | 2011 | 2 | |
| 16 | 2018 | 2 | |
| 17 | 2012 | 1 | |
| 18 | 2016 | 1 |
About Thomas Goddemeier
Thomas Goddemeier is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Otorhinolaryngology, having authored 18 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), DNA Repair Mechanisms (5 papers), Cancer-related Molecular Pathways (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer therapeutics and mechanisms (3 papers), Neuroblastoma Research and Treatments (2 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Oncology (966 citations), Pulmonary and Respiratory Medicine (930 citations), Cancer Research (179 citations), Otorhinolaryngology (29 citations) and Hepatology (43 citations). Thomas Goddemeier has collaborated with scholars based in Germany, United Kingdom and United States. Frequent co-authors include Wilfried Eberhardt, Robert Pirker, Joachim von Pawel, Kenneth J. O’Byrne, Filippo de Marinis, Ihor Vynnychenko, U. Gatzemeier, Maciej Krzakowski, Michael Emig and Chih-Teng Yu. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Lung Cancer, Annals of Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.